Pazopanib (Teva) 200 mg tablets: Supply issue

Last Updated: 3 June 2026

Supply issue Section 29A Active

Due to manufacturing changes, there is limited stock of the 200 mg strength of pazopanib tablets (Pharmacode: 2695332).

3 June 2026 | Teva brand arrived

Teva advises that Pazopanib Teva tablets are available again. There may still be some Pazopanib ADVZ at wholesaler level. The ADVZ brand will remain funded for some time to allow pharmacies time to dispense and claim for it.

Affected product

Teva, the supplier, will run out of the following product:

Chemical: Pazopanib
Presentation: Tab 200 mg
Brand: Pazopanib Teva
Pharmacode: 2695332
Subsidy: $172.88
Measure / Qty: per 30

The 400 mg is not affected by this supply issue.

Schedule listing for pazopanib(external link)

Alternative funded from 1 April

The following product was funded in the Schedule from 1 April 2026. It is not Medsafe approved and will need to be prescribed and dispensed in line with section 29A of the Medicines Act.

Chemical: Pazopanib
Presentation: Tab 200 mg
Brand: Pazopanib ADVZ
Pharmacode: 2726645
Subsidy: $172.88
Measure / Qty: per 30

Section 29 and OP apply.

General Supply Issue A5 Flier [PDF 111 KB]

Resupplied early June 2026

Teva has stock available again for wholesalers to order from early June 2026. It can take another 1 to 2 weeks to reach pharmacies around the country.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.